Company Jaguar Health, Inc.

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 23/01/2026 am IST			5-day change	1st Jan Change
0.7300 ^USD	-9.78%		-4.51%	-21.61%

16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI

Business description: Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Number of employees: 49

Sales by Activity: Jaguar Health, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Human Health	93.09L	42.73L	1.17Cr	95.88L	1.14Cr
Animal Health	76T	62T	2L	2L	3L

See all business segments

Geographical breakdown of sales: Jaguar Health, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)

See all geographic segments

Executive Committee: Jaguar Health, Inc.

Manager	Title	Age	Since
Lisa Conte CEO	Chief Executive Officer	67	06/06/2013
Carol Lizak DFI	Director of Finance/CFO	62	13/08/2019
Jonathan Wolin CMP	Compliance Officer	64	01/11/2018
Pravin Ramsewak Chaturvedi CTO	Chief Tech/Sci/R&D Officer	63	01/03/2022
Massimo Radaelli PRN	Corporate Officer/Principal	67	02/04/2024

See JAGUAR HEALTH, INC. governance

Composition of the Board of Directors: Jaguar Health, Inc.

Director	Title	Age	Since
Lisa Conte BRD	Director/Board Member	67	06/06/2013
James Bochnowski CHM	Chairman	82	01/06/2014
John Micek BRD	Director/Board Member	73	01/04/2016
Jonathan Siegel BRD	Director/Board Member	52	29/03/2018
Anula Kusum Jayasuriya BRD	Director/Board Member	69	01/07/2022

Composition of the Board of Directors

Shareholders: Jaguar Health, Inc.

Name	Equities	%	Valuation
Lincoln Alternative Strategies LLC 13.34 %	6,00,000	13.34 %	558 600 $
Joshua Mailman 13.06 %	5,87,320	13.06 %	546 795 $
Iliad Management Ltd. 9.784 %	4,40,000	9.784 %	409 640 $
Brown Stone Capital Ltd. 3.593 %	1,61,583	3.593 %	150 434 $
DRW Securities LLC 2.023 %	90,968	2.023 %	84 691 $

Name	Equities	%	Valuation
Streeterville Management LLC 81.82 %	99	81.82 %	92 $
Iliad Management Ltd. 18.18 %	22	18.18 %	20 $

Name	Equities	%	Valuation
Iliad Management Ltd. 65.38 %	170	65.38 %	158 $
Streeterville Management LLC 34.62 %	90	34.62 %	84 $

List of JAGUAR HEALTH, INC. shareholders

Company details: Jaguar Health, Inc.

Jaguar Health, Inc.

200 Pine Street

94104, San Francisco

http://www.jaguar.health

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
JAGUAR HEALTH, INC.	-9.78%	-4.51%	-96.49%	-99.99%	33.12L
ELI LILLY AND COMPANY	+0.82%	+5.27%	+44.22%	+214.21%	97TCr
JOHNSON & JOHNSON	+0.22%	-0.49%	+50.40%	+29.48%	53TCr
ABBVIE INC.	+0.91%	+0.63%	+28.91%	+45.81%	39TCr
ROCHE HOLDING AG	-0.13%	-0.34%	+26.71%	+17.68%	38TCr
ASTRAZENECA PLC	+0.57%	-2.90%	+23.52%	+23.61%	28TCr
NOVARTIS AG	+0.53%	+0.07%	+28.16%	+35.41%	28TCr
NOVO NORDISK A/S	+2.28%	+4.22%	-30.24%	-16.04%	28TCr
MERCK & CO., INC.	-1.74%	-1.61%	+14.11%	-0.69%	27TCr
AMGEN INC.	+1.01%	+5.16%	+26.93%	+31.85%	19TCr
Average	+0.10%	+1.09%	+11.62%	+28.13%	35.6TCr
Weighted average by Cap.	+0.14%	+2.10%	+29.72%	+74.81%